Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Holding DARE?
Track your performance easily
DARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.05 - $10.72
Previous Close$4.16
Volume43.02K
Average Volume (3M)42.63K
Market Cap
$34.44M
Enterprise Value$19.57M
Total Cash (Recent Filing)$16.40M
Total Debt (Recent Filing)$1.52M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 14, 2024EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding8,546,361
10 Day Avg. Volume46,311
30 Day Avg. Volume42,632
Standard Deviation0.23
R-Squared0.09
Alpha-0.00710
Financial Highlights & Ratios
Price to Book (P/B)13.42
Price to Sales (P/S)12.13
Price to Cash Flow (P/CF)0.70
P/FCF Ratio0.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.96
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$12.50Price Target Upside200.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Daré Bioscience News
PremiumCompany Announcements
Daré Bioscience Enhances Investor Engagement with New Presentation
PremiumCompany Announcements
Daré Bioscience Secures Funding for HPV Treatment
PremiumCompany Announcements
Daré Bioscience Secures $15M Funding through Stock Agreement
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDaré reported net income of $12.9M, largely attributed to $20.4M in net proceeds from the non-dilutive royalty agreement with XOMA LLC.
Funding And DevelopmentDaré Bioscience has been selected to receive up to $10M in funding to support the development of its DARE-HPV program, which could become the first FDA-approved pharmaceutical intervention for HPV-related cervical diseases.
Innovative ContraceptiveOvaprene would be the first monthly, hormone-free contraceptive for women who cannot or prefer not to use hormone-based birth control products.
Bears Say
Clinical DevelopmentThe halfway mark of enrollment, or n=125 women, will not complete the six months of Ovaprene use until the end of 2Q25.
Financial RisksDaré faces financial risks as it requires capital greater than its current cash balance and may need to raise additional funds, which could be dilutive.
Regulatory And Commercial RisksThere are regulatory risks involved for Daré as approval is needed for the products in development, and commercial risks due to competition and Covid-19.
---
Ownership Overview
12.45%
Insiders
1.06% Mutual Funds
1.18% Other Institutional Investors
81.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $3.05 and its highest was $10.72 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Currently, no data Available
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Nov 14, 2024 which is in 4 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Aug 12, 2024. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of -$0.039 by $1.559.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -$0.69.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 8,546,361 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of $1.52 in its last earnings report, beating expectations of -$0.039. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Daré Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (200.47% Upside)
$12.50 (200.47% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.71%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
---
DARE Earnings Call
Q2 2024
0:00 / 0:00
---
DARE Stock 12 Month Forecast
Average Price Target
$12.50
▲(200.47% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-41.61%
reiterated a buy rating 17 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -41.61% per trade.
---